Home
Drugs
Targets
Pathways
Ontologies
Cyp450s
Adv.search
Help/FAQ

Drug-Target Interaction

Drug

show drug details
PubChem ID:3715
Structure:
Synonyms:
(1-p-Chlorobenzoyl-5-methoxy-2-methylindol-3-yl)acetic acid
1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid
1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid & MAP-30
1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-3-indoleacetic acid
1-(p-Chlorbenzoyl)-5-methoxy-2-methylindol-3-essigsaeure
1-(p-Chlorbenzoyl)-5-methoxy-2-methylindol-3-essigsaeure [German]
1-(p-Chlorobenzoyl)-2-methoxy-3-methyl-1H-indole-3-acetic Acid
1-(p-chlorobenzoyl)-2-methyl-5-methoxy-3-indoleacetic acid
1-(p-Chlorobenzoyl)-2-methyl-5-methoxyindole-3-acetic acid
1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indolylacetic acid
1-(p-Chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid
1-p-Cloro-benzoil-5-metoxi-2-metilindol-3-acido acetico
1-p-Cloro-benzoil-5-metoxi-2-metilindol-3-acido acetico [Spanish]
1-[p-Chlorobenzoyl]-5-methoxy-2-methylindole-3-acetic acid
1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-
1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- (9CI)
1z9h
2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetic acid
37242-43-6
5-22-05-00239 (Beilstein Handbook Reference)
503560-73-4
53-86-1
74252-25-8
74252-25-8 (hydrochloride salt, tri-hydrate)
7681-54-1
7681-54-1 (hydrochloride salt)
91853-74-6
AB00052022
AC-532
AC1L1GJQ
Aconip
Aconip (TN)
AIDS-025351
AIDS-028381
AIDS025351
AIDS028381
AKOS000592893
alpha-(1-(p-Chlorobenzoyl)-2-methyl-5-methoxy-3-indolyl)acetic acid
Amuno
Apo-Indomethacin
Argun
Arthrexin
Artracin
Artrinovo
Artrivia
BIDD:GT0132
BIM-0050670.0001
Bio-0704
Bio2_000405
Bio2_000885
Bonidin
Bonidon
Bonidon Gel
BPBio1_000160
BRD-K57222227-001-06-1
BRN 0497341
BSPBio_000144
BSPBio_001149
BSPBio_002176
C01926
C19H16ClNO4
CAS-53-86-1
Catlep
CCG-40186
CCRIS 3502
CGIGDMFJXJATDK-UHFFFAOYSA-
CHEBI:49662
CHEMBL6
Chibro-Amuno
Chrono-indicid
Chrono-indocid
Confortid
CPD-10545
D00141
DB00328
DESMETHYL INDOMETHACIN
DivK1c_000271
Dolcidium
Dolcidium PL
Dolovin
Durametacin
EINECS 200-186-5
Elmetacin
EU-0100692
Flexin continus
Hicin
HMS1362I11
HMS1568H06
HMS1792I11
HMS1920F21
HMS1990I11
HMS2089N19
HMS2091N09
HMS2095H06
HMS2231J10
HMS3262K05
HMS500N13
HSDB 3101
I 7378
I0655
I7378_SIGMA
I8280_SIGMA
IDI1_000271
IDI1_002160
Idomethine
Imbrilon
IMN
IN1454
Inacid
Indacin
Indameth
Indmethacine
INDO-LEMMON
Indo-Phlogont
Indo-rectolmin
Indo-Spray
Indo-tablinen
Indocid
Indocid (pharmaceutical)
Indocid Pda
Indocid Sr
Indocin
Indocin (TN)
Indocin I.V
Indocin I.V.
INDOCIN SR
Indolar SR
Indole-3-acetic acid, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl-
Indole-3-acetic acid, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl- (8CI)
Indomecol
Indomed
Indomee
Indomet 140
Indometacin
Indometacin (JP15/INN)
Indometacin (JP16/INN)
Indometacina
Indometacina [INN-Spanish]
Indometacine
Indometacine [INN-French]
Indometacinum
Indometacinum [INN-Latin]
Indometacyna
Indometacyna [Polish]
Indomethacin
Indomethacin & MAP-30
Indomethacin (USP)
Indomethacin [USAN:BAN]
Indomethacin, Indochron E-R, Indocin-SR, Indocid, Indocin, Indomethacin
Indomethacin-Supplied by Selleck Chemicals
Indomethacine
Indomethacinum
Indomethancin
Indomethazine
INDOMETHEGAN
Indomethine
Indometicina
Indometicina [Spanish]
Indomo
Indomod
Indoptic
Indoptol
Indorektal
Indoxen
Inflazon
Infrocin
Inteban SP
KBio1_000271
KBio2_000489
KBio2_001399
KBio2_003057
KBio2_003967
KBio2_005625
KBio2_006535
KBio3_000897
KBio3_000898
KBio3_001396
KBioGR_000395
KBioGR_000489
KBioSS_000489
KBioSS_001399
Kwas 1-(p-chlorobenzoilo)-2-metylo-5-metoksy-3-indolilooctowy
Kwas 1-(p-chlorobenzoilo)-2-metylo-5-metoksy-3-indolilooctowy [Polish]
L000959
Lausit
Liometacen
Lopac-I-7378
Lopac0_000692
LS-187
LS-82147
Metacen
Metartril
Methazine
Metindol
Mezlin
Mezlocillin
Mezolin
Miametan
Mikametan
MLS000069402
MLS000758212
MLS001074194
Mobilan
MolMap_000032
N-p-Chlorbenzoyl-5-methoxy-2-methylindole-3-acetic acid
NCGC00015562-01
NCGC00015562-02
NCGC00015562-03
NCGC00015562-04
NCGC00015562-05
NCGC00015562-06
NCGC00015562-07
NCGC00015562-08
NCGC00015562-09
NCGC00015562-10
NCGC00015562-11
NCGC00015562-12
NCGC00015562-13
NCGC00015562-14
NCGC00015562-15
NCGC00015562-16
NCGC00015562-17
NCGC00015562-18
NCGC00015562-19
NCGC00015562-20
NCGC00015562-21
NCGC00015562-22
NCGC00024135-02
NCGC00024135-04
NCGC00024135-05
NCGC00024135-06
NCGC00024135-07
NCGC00024135-08
NCGC00024135-09
NCGC00024135-10
NCGC00024135-11
NCGC00024135-12
NCGC00024135-13
NCGC00024135-14
NCGC00024135-15
nchembio.147-comp11
NCI-C56144
NCI60_041708
NINDS_000271
Novo-Methacin
Novomethacin
Nu-Indo
Oprea1_686105
Osmosin
Prestwick0_000272
Prestwick1_000272
Prestwick2_000272
Prestwick3_000272
Prestwick_597
Reumacide
Rhemacin LA
Rheumacin LA
S00108
S1723_Selleck
Sadoreum
SMR000058195
SMR000449290
SPBio_000979
SPBio_002363
SPECTRUM1500350
Spectrum2_000970
Spectrum3_000468
Spectrum4_000018
Spectrum5_000868
Spectrum_000919
ST5320042
Tannex
Tocris-1708
UNII-XXE1CET956
UPCMLD-DP023
UPCMLD-DP023:001
USAN
Vonum
[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetic acid
ATC-Codes:
Side-Effects:
Side-EffectFrequency
fasciitis0.0010
leukemia0.00075
thrombophlebitis0.00075
urinary frequency0.00075
purpura0.0
palpitations0.0
paresthesia0.0
peptic ulcer0.0
peripheral neuropathy0.0
petechiae0.0
proctitis0.0
retrolental fibroplasia0.0
pruritus0.0
renal failure0.0
pulmonary edema0.0
proteinuria0.0
hypertension0.0
pulmonary hypertension0.0
hypoglycemia0.0
hyponatremia0.0
fall in blood pressure0.0
infection0.0
jaundice0.0
pain0.0
leukopenia0.0
nausea0.0
interstitial nephritis0.0
nephrotic syndrome0.0
nervousness0.0
osteoarthritis0.0
shock0.0
ankylosing spondylitis0.0
stevens - johnson syndrome0.0
intestinal ulceration0.0
lightheadedness0.0
malaise0.0
epigastric pain0.0
parkinsonism0.0
rectal bleeding0.0
electrolyte imbalance0.0
blurred vision0.0
bradycardia0.0
preterm infant0.0
insomnia0.0
bloating0.0
muscle weakness0.0
vaginal bleeding0.0
intracranial bleeding0.0
ulcerative stomatitis0.0
sweating0.0
syncope0.0
tachycardia0.0
tinnitus0.0
ulcer0.0
uremia0.0
urticaria0.0
angiitis0.0
vertigo0.0
vomiting0.0
weight gain0.0
renal insufficiency0.0
hypersensitivity0.0
abdominal distention0.0
asthma0.0
carcinoma0.0
chest pain0.0
ulcerative colitis0.0
coma0.0
mental confusion0.0
constipation0.0
convulsions0.0
deafness0.0
exfoliative dermatitis0.0
diarrhea0.0
diplopia0.0
dizziness0.0
rheumatoid arthritis0.0
gouty arthritis0.0
acidosis0.0
agranulocytosis0.0
alkalosis0.0
loss of hair0.0
anaphylaxis0.0
anemia0.0
aplastic anemia0.0
hemolytic anemia0.0
angioedema0.0
anorexia0.0
anxiety0.0
apnea0.0
arrhythmia0.0
somnolence0.0
patent ductus arteriosus0.0
rash0.0
fatigue0.0
flatulence0.0
flushing0.0
gastroenteritis0.0
gastrointestinal bleeding0.0
glycosuria0.0
gynecomastia0.0
headache0.0
congestive heart failure0.0
heartburn0.0
hematuria0.0
hemorrhage0.0
hyperglycemia0.0
erythema nodosum0.0
hyperkalemia0.0
dysarthria0.0
indigestion0.0
dyspnea0.0
ecchymosis0.0
edema0.0
enterocolitis0.0
toxic epidermal necrolysis0.0
epistaxis0.0
epilepsy0.0
erythema multiforme0.0
seizures0
stomatitis0
apathy0
muzziness0
erythema0
depersonalization0
fever0
pneumothorax0
tenesmus0
clotting0

Target

show target details
Uniprot ID:MMP9_RAT
Synonyms:
92 kDa gelatinase
92 kDa type IV collagenase
Gelatinase B
GELB
Matrix metalloproteinase-9
MMP-9
EC-Numbers:3.4.24.35
Organism:Rat
Rattus norvegicus
PDB IDs:-

Binding Affinities:

Ki: Kd:Ic 50:Ec50/Ic50:
----

References:

15770365
Suppression of experimental aortic aneurysms: comparison of inducible nitric oxide synthase and cyclooxygenase inhibitors.. Peter J Armstrong; David P Franklin; David J Carey; James R Elmore (2005) Annals of vascular surgery display abstract
The rat model of abdominal aortic aneurysm (AAA) is associated with inflammation, destruction of extracellular matrix, and production of both inducible nitric oxide synthase (iNOS) and matrix metalloproteinase-9 (MMP-9). Indomethacin, a nonselective cyclooxygenase inhibitor, may prevent AAA formation by inhibiting cyclooxygenase-2 (COX-2) activity. We hypothesized that indomethacin, rofecoxib (selective COX-2 inhibitor), and 1400 W (selective iNOS activity inhibitor) would decrease aneurysm formation in the rat model. Forty-six male Wistar rats underwent intraaortic elastase infusion in two parallel studies based on medication delivery route. Sixteen rats were randomized to rofecoxib or water by gastric lavage. Thirty rats were randomized to subcutaneous saline, indomethacin, or 1400 W. Heart rate, blood pressure and aortic diameters were measured. Western Blot and mRNA analysis for MMP-9 and iNOS was performed on postoperative day 7 aortic segments. Elastin degradation and inflammation were evaluated by immunohistochemistry. Elastase infusion produced AAA in all rats. 1400 W significantly limited aneurysm expansion (p = 0.01) whereas treatment with indomethacin and rofecoxib did not. Only 1400 W significantly increased blood pressure (p < 0.001). Indomethacin alone statistically decreased MMP-9 (p < 0.011). 1400 W resulted in greater conservation of aortic elastin than indomethacin (p = 0.025). All groups demonstrated statistically similar expression of iNOS. In conclusion, selective iNOS activity inhibitor, 1400 W, significantly decreased aneurysm size and preserved aortic elastin without altering MMP-9 levels. Indomethacin significantly decreased MMP-9 expression without decreasing aneurysm size. Rofecoxib did not significantly decrease MMP-9 expression or aneurysm size. Inhibition of iNOS limits aneurysmal expansion by mechanisms other than MMP-9 inhibition. MMP-9 inhibition by indomethacin is not sufficient to limit aneurysm expansion in our model.